Latest Edition
Friday, June 26, 2026
The day's most important peptide therapy updates — research, dosing, safety, products, and regulatory news — compressed for pet owners and veterinary professionals.
A full week in pet peptide therapy: interest in BPC-157 for canine recovery keeps rising, dosing and sourcing remain the biggest safety concerns, and new veterinary research on joint health offers a genuinely encouraging — if preliminary — data point. Here is what pet owners and veterinary professionals need to know.
INSIGHT ·The rodent research is genuinely interesting for tissue healing, but there's a real gap between preclinical findings and validated protocols for a specific dog or cat. Sourcing and veterinary oversight matter more than the hype.
INSIGHT ·Weight, species, and route all shape a safe dose. The most dangerous shortcut is copying a human protocol. Compounding pharmacies working with veterinarians remain the safest path for owners considering peptides.
INSIGHT ·A small veterinary study reported mobility improvements in dogs with osteoarthritis and a favorable short-term safety profile. Encouraging, but preliminary — a reason for informed conversations, not a green light.
INSIGHT ·The biggest risk in pet peptide therapy is often product quality, not the peptide itself. If you can't trace where a peptide came from and how it was made, it doesn't belong in your pet.
Get this briefing in your inbox weekly.
Subscribe →